Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
MONTPELLIER, France, April 05, 2016 -- MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, has announced the sale of ten new ROSA™ robots during the third fiscal quarter 2016 (January 1 to March 31, 2016).
Seven robots were sold in the United States, two were sold in China and one was sold in France. In comparison, five sales were made during the same period the previous year.
Bertin Nahum, CEO and Founder of Medtech, commented: “This quarter has been particularly active from a commercial viewpoint with ten new sales of our ROSA™ robot. The performance reflects the continued momentum of our development and confirms our growth strategy to drive adoption of the ROSA™ robot across international markets.”
Sales made during the fiscal third quarter in detail:
United States:
Mount Sinai Hospital (New York City, New York) acquired two ROSA™ robots for performing minimally invasive brain surgery. This establishment of national and international renown for the treatment of central nervous system disorders is ranked among the fifteen best American hospitals by U.S. News & World Report.
Akron Children’s Hospital (Akron, Ohio), is a pediatric hospital, specializing particularly in the treatment of epilepsy. In 2015, it was ranked among the 30 best American hospitals for children by U.S. News & World Report.
The Yale Comprehensive Epilepsy Center (New Haven, Connecticut) provides promising treatment options for many adult and pediatric patients. Yale is also internationally recognized for its clinical excellence and innovative research.
Miami Valley (Dayton, Ohio) is a well-known medical facility and winner of the Healthgrades® “America’s 100 Best Hospitals’ Award” for 2016. It also received the Healthgrades® Distinguished Hospital Award–Clinical Excellence for three consecutive years, from 2014 to 2016.
Brigham and Women's Hospital (Boston, Massachusetts), is one of America’s most prestigious hospitals and has been recognized as one of the 10 best American hospitals by U.S. News & World Report.
University of Colorado Hospital (Aurora, Colorado), is a renowned institution, particularly for neurology and neurosurgery. In 2015, it was ranked as the best hospital in the state of Colorado by U.S. News & World Report.
China:
Two new sales of ROSA™ were made in China, a dynamic market in Asia representing a strong growth opportunity for Medtech. There are now nine ROSA™ robots installed in China.
France:
Rouen University Hospital, is a benchmark hospital in the field of neurosurgery, especially for the treatment of epilepsy. It was ranked among the ten best French Hospitals by Le Point magazine for its management of patients with this disorder.
Next planned communication: release of 2015/2016 Q3 financial report (fiscal period ended 3/31/2016), on April 7, 2016.
About MEDTECH
Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.
In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
CONTACT MEDTECH Christophe Sibillin Chief Financial Officer Tel : +33 (0)4 67 10 77 40 INVESTORS Corinne Puissant Tel : +33 (0)1 53 67 36 77 [email protected] PRESS Alexandra Prisa (EU) Tel. : +33(0)1 53 67 36 90 [email protected] Joanna Zimmerman (US) Tel : +1 646-536-7006 [email protected]
